Search

Maralixibat

with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients with Alagille syndrome. It was granted FDA approval on 29 September 2021.

Metyrosine

It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.

Tralokinumab

US in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the

mRNA-1345

mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]

Fostamatinib

It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK

Solifenacin

[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.

Iron protein succinylate

Formestane

Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency. … Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.

Polidocanol

Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower … The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.

Trihexyphenidyl

[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. … [L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]